ArticleGene therapy2001
Gene delivery from the E3 region of replicating human adenovirus: evaluation of the E3B region.
Article in Gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Development of Oncolytic Vectors Based on Human Adenovirus Type 6 for Cancer Treatment.Viruses · 2023Article
- Concepts in Oncolytic Adenovirus Therapy.International journal of molecular sciences · 2021Review
- Arming Oncolytic Adenoviruses: Effect of Insertion Site and Splice Acceptor on Transgene Expression and Viral Fitness.International journal of molecular sciences · 2020Article
- Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses.Cancers · 2020Review
- Homologous recombination in E3 genes of human adenovirus species D.Journal of virology · 2013Article
- Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers.Cancer gene therapy · 2013Review
- Oncolytic viruses: the power of directed evolution.Advances in virology · 2012Article
- Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer.Cancer gene therapy · 2010Article
- Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy.Gene therapy · 2010Article
- Increasing the efficacy of oncolytic adenovirus vectors.Viruses · 2010Article
- Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma.Cancer science · 2010Article
- Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.Cancer gene therapy · 2009Article
- Armed replicating adenoviruses for cancer virotherapy.Cancer gene therapy · 2009Review
- Adenoviral vector-based strategies for cancer therapy.Current drug therapy · 2009Article
- Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors.Journal of virology · 2009Article
- Comparison of the E3 and L3 regions for arming oncolytic adenoviruses to achieve a high level of tumor-specific transgene expression.Cancer gene therapy · 2008Article
- The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR).Cancer gene therapy · 2007Article
- Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors.Cancer gene therapy · 2007Article
- Core labeling of adenovirus with EGFP.Virology · 2006Article
- Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53.Cancer gene therapy · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Successful therapies for cancer need to deal with the complexity associated with the human tumor. Studies of tumor and viral biology have progressed to a point where replicating viruses are now being engineered as potential treatments for human cancers. The complex nature of human cancers dictates that successful treatments will require combination therapies. To this end, we have focused on developing the gene delivery capacity of the replicating adenovirus, using the non-essential E3 region transcription unit as a target site for therapeutic transgene insertions. Utilizing the endogenous expression machinery of the E3 region (promoter, splicing, polyA) we show that a therapeutic transgene, TNF, is efficiently expressed from the E3B region and with exclusive late gene expression kinetics. Potential clinical applications are discussed.
Indexed as
Identifiers
11509944What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.